Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833794 | 0.89 | CNR2 (0.47) | CNR2TRPA1ALBHTTTSHR | |
| SCHEMBL6834434 | 0.87 | CNR2 (0.50) | CNR2TRPA1ALBHTTTSHR | |
| SCHEMBL6834081 | 0.86 | CCR2 (0.55) | CNR2ALBCCR9F10CCR2 | |
| SCHEMBL6834180 | 0.85 | CNR2 (0.53) | CNR2TRPA1ALBHTTTSHR | |
| SCHEMBL6835700 | 0.85 | CNR2 (0.48) | CNR2TRPA1ALBHTTTSHR | |
| SCHEMBL6833926 | 0.85 | ALB (0.46) | CNR2TRPA1ALBHTTALDH1A1 | |
| SCHEMBL6833953 | 0.85 | SERPINE1 (0.48) | HTTTSHRALDH1A1F10CCR2 | |
| SCHEMBL6830678 | 0.85 | AKR1C2 (0.48) | CNR2HTTTSHRALDH1A1KMT2A | |
| SCHEMBL6830403 | 0.85 | CNR2 (0.55) | CNR2TRPA1ALBHTTTSHR | |
| SCHEMBL6833877 | 0.84 | CNR2 (0.45) | CNR2TRPA1ALBHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CNR2 3495/4885TRPA1 377/4885ALB 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.